Roche Diagnostics Cites Ind-Swift’s “Hunger To Grow” As The Two Team Up To Market Heart Attack Diagnostic In India
This article was originally published in PharmAsia News
Roche Diagnostics chooses Ind-Swift in India as marketing partner for TROP T assay to detect heart attacks.
You may also be interested in...
MUMBAI - Roche Diagnostics India (Pvt) Ltd. Chairman and Managing Director Bhuvnesh Agarwal believes the company has benefited from the unprecedented surge in market growth, but still finds public awareness to be an issue when it comes to the most advanced diagnostics available to patients
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.